real-time news and commentary for investors
Wednesday, Aug 8
2012, 4:09 PM
Amgen (AMGN) says that based upon the recommendation of an independent Data Monitoring...
Amgen (AMGN) says that based upon the recommendation of an independent Data Monitoring Committee, it's terminating its Phase 3 study of its pancreatic cancer drug Ganitumab. After reviewing the pre-planned interim analysis, the committee concluded that the drug was unlikely to demonstrate a statistically significant improvement towards the primary endpoint of overall survival. Shares -0.9% AH.